Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04231643 |
Recruitment Status :
Recruiting
First Posted : January 18, 2020
Last Update Posted : June 27, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bipolar Disorder | Drug: Dronabinol Drug: Epidiolex Drug: Placebos | Early Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 144 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Basic Science |
Official Title: | A Randomized, Controlled Trial of Cannabis in Bipolar Disorder Patients and Healthy Volunteers Evaluating Cognition and Endocannabinoid Levels |
Actual Study Start Date : | September 1, 2021 |
Estimated Primary Completion Date : | February 28, 2023 |
Estimated Study Completion Date : | February 28, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Bipolar Disorder
adults with bipolar disorder
|
Drug: Dronabinol
one-time oral administration of 5 mg dronabinol Drug: Epidiolex one-time oral administration of 600 mg Epidiolex Drug: Placebos one-time oral administration of placebo |
Active Comparator: Healthy Volunteers
adults with no psychiatric disease
|
Drug: Dronabinol
one-time oral administration of 5 mg dronabinol Drug: Epidiolex one-time oral administration of 600 mg Epidiolex Drug: Placebos one-time oral administration of placebo |
- Score on Iowa Gambling Task [ Time Frame: one day ]This is an experimental measure and not a scale with specific anchor points. Lower scores reflect increased risk-taking
- Score on Progressive Ratio Test [ Time Frame: one day ]This is an experimental measure and not a scale with specific anchor points. Higher scores indicate increased willingness to work for a reward
- Scores on Probabilistic Learning Task [ Time Frame: one day ]This is an experimental measure and not a scale with specific anchor points. Measures decision-making strategies such as win-stay, lose-shift.
- Scores on Continuous Performance Task [ Time Frame: one day ]This is an experimental measure and not a scale with specific anchor points. Higher scores reflect better attention and ability to discriminate important information from unimportant information
- Percent Prepulse Inhibition (PPI) [ Time Frame: one day ]This is a physiological measure and not a scale with specific anchor points. Higher percent PPI reflects better sensorimotor gating
- motor activity in the human Behavioral Pattern Monitor [ Time Frame: one day ]This is an experimental measure and not a scale with specific anchor points. Subjects' behavior in an open field (a room filled with novel objects) is quantified over a 15-minute period via amount of motor activity as measured by a wearable accelerometer. Increased motor activity reflects increased tendency to engage in exploratory behavior.
- object interactions in the human Behavioral Pattern Monitor [ Time Frame: one day ]This is an experimental measure and not a scale with specific anchor points. Subjects' behavior in an open field (a room filled with novel objects) is quantified over a 15-minute period via video ratings that quantify number of interactions with novel objects. Increased object interactions reflects increased novelty-seeking behavior.
- cerebrospinal fluid levels of anandamide [ Time Frame: one day ]Reflects increased availability of the endogenous cannabinoid anandamide in the brain

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Participants will be asked about which gender they identify with |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- For subjects in BD group, DSM-5 criteria for Bipolar Disorder as determined by the Structured Clinical Interview for DSM-5 (SCID).
- Young Mania Rating Scale (YMRS) < 12.
- Infrequent cannabis use as defined by a history of cannabis use and current use no more than 4 times per month.
- Willing to abstain from cannabis use for at least two days prior to the experimental visit.
Exclusion Criteria:
- Hamilton Depression Rating Scale (HDRS) score > 10.
- Suicidality. Exposure to cannabis does not lead to depression but it may be associated with suicidal thoughts and attempts. Therefore, the Center for Epidemiological Studies-Depression Scale (CES-D) subscale measuring suicidal ideation ("I wished I were dead". "I wanted to hurt myself") will be completed. Should any of these items be answered affirmatively, e.g., the subject has endorsed these items for at least 1-2 days in the last week, the subject will not be enrolled in the study.
- The Substance Abuse Module of the Diagnostic Interview Schedule for DSM-5 will be administered to exclude individuals with current substance use disorders.
- Clinically significant or unstable medical condition. Subjects will undergo a medical evaluation (H&P, toxicology screening, and for females of childbearing potential, pregnancy testing (utilizing a human chorionic gonadotropin (hCG) urine test). Individuals with significant cardiovascular disease (e.g., angina, myocardial infarction or stroke), hepatic or renal disease, uncontrolled hypertension, and chronic pulmonary disease (e.g., asthma, COPD), will be excluded. With respect to cardiovascular and pulmonary status, a clinician will screen participants with a tool developed for this purpose (Appendix 3 Cardiopulmonary Screen). Hepatic and renal disease will be evaluated with liver and renal function laboratory tests. Females who are pregnant or lactating will be excluded.
- Infections - evidence of skin infection at lumbar puncture site.
- To avoid confounding of cognitive testing, a neurological disorder such as seizures, stroke, Parkinson's disease, dementia, or a history of head injury with loss of consciousness for at least 15 minutes will be excluded.
- Unwilling to refrain from driving or operate heavy machinery for four hours after consuming study medication. This criterion is consistent with current expert recommendations on driving following the use of cannabis.
- Additionally, because the hBPM paradigm requires participants to be ambulatory, those who cannot ambulate independently (e.g., require a wheelchair) or those who have a motor disease (e.g., multiple sclerosis, cerebral palsy) will be excluded.
- A previous adverse reaction to cannabinoids will be cause for exclusion as will a historical diagnosis of cannabis use disorder.
- Positive result on Draeger 5000 test indicating recent cannabis use.
- Unwillingness to prevent pregnancy during the cannabinoid administration portion of the study (using birth control in female participants of child-bearing age) Acceptable methods of birth control are: oral contraceptive pills, diaphragm, condom, progestin implant, intrauterine contraceptive device, sterilization, etc.
- Any active opportunistic infection or malignant condition requiring acute treatment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04231643
Contact: Elizabeth Peek, BA | 6195436575 | eypeek@health.ucsd.edu |
United States, California | |
UC San Diego Medical Center | Recruiting |
San Diego, California, United States, 92103 | |
Contact: Elizabeth Peek, BA 619-543-6575 eypeek@health.ucsd.edu |
Principal Investigator: | William Perry, PhD | UCSD |
Responsible Party: | William Perry, Professor in Residence of Psychiatry, University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT04231643 |
Other Study ID Numbers: |
180356 R01DA043535 ( U.S. NIH Grant/Contract ) |
First Posted: | January 18, 2020 Key Record Dates |
Last Update Posted: | June 27, 2022 |
Last Verified: | June 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
cannabidiol THC |
Bipolar Disorder Bipolar and Related Disorders Mental Disorders Dronabinol Cannabidiol Hallucinogens Physiological Effects of Drugs Psychotropic Drugs Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Cannabinoid Receptor Agonists Cannabinoid Receptor Modulators Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Anticonvulsants |